Testing a new RNA vaccine for Crimean-Congo hemorrhagic fever
Part of Infections clinical trials.
This trial is testing an investigational RNA vaccine to see if it is safe and helps your body build immunity against Crimean-Congo hemorrhagic fever, a serious viral disease. The study involves two injections and follow-up visits over several months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 64 years old.
- Your body mass index (BMI) must be between 17 and 35.
- You need to be in good general health, with no serious medical conditions like heart disease, lung disease, autoimmune disorders, or recent cancer.
- You must agree to use effective birth control (if you could become pregnant) for at least 30 days before and 60 days after the last injection.
- You cannot have donated blood or received any other vaccines within 30 days before or during the study.
- You cannot be pregnant, breastfeeding, or have a history of severe allergic reactions to vaccines or related antibiotics.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different treatments for Crimean-Congo hemorrhagic fever (CCHF), a serious viral infection. It aims to find which treatment is safe and works best for patients who are hospitalized with the disease.
This study tests an experimental HIV vaccine that uses tiny particles and mRNA technology in healthy adults. If you qualify, you'll help researchers see if it's safe and if it triggers an immune response.
This trial is developing a quick, point-of-care diagnostic test for Crimean-Congo hemorrhagic fever (CCHF), a serious viral illness. If you have symptoms and are being tested for CCHF, this study could help confirm the diagnosis faster.
This study tests two experimental mRNA-based HIV vaccines to see if they are safe and create an immune response. It is for healthy adults aged 18 to 55 who do not have HIV.
This study tests a new injectable drug (VH4011499) for safety and how the body processes it. It's for healthy adults without HIV, and participants will get either the study drug or a placebo (an inactive shot).
This trial tests how the dengue virus affects healthy adults who have never been exposed to dengue or similar viruses. You would be given a controlled dose of the virus and closely monitored to help researchers understand the infection and develop better treatments or vaccines.
Hear when a new Vaccine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.